| Placebo (N = 27) | Namilumab | ||
---|---|---|---|---|
20 mg (N = 28) | 80 mg (N = 25) | 150 mg (N = 28) | ||
Mean duration of RA at screening, years | 10.04 ± 8.880 | 9.02 ± 7.476 | 8.62 ± 8.501 | 7.35 ± 4.976 |
Positive rheumatoid factor at baseline | 16 (59.3) | 16 (57.1) | 12 (48.0) | 18 (64.3) |
Anti-citrullinated peptide antibodies at baseline | 20 (74.1) | 19 (67.9) | 12 (48) | 21 (75) |
Mean MTX dose at baseline, mg/week | 15.73 ± 4.04 | 16.54 ± 4.741 | 16.06 ± 4.370 | 15.96 ± 4.238 |
Type of failure of prior treatment | ||||
 MTX-IR | 23 (85.2) | 23 (82.1) | 22 (88.0) | 24 (85.7) |
 TNF-IR | 4 (14.8) | 5 (17.9) | 3 (12.0) | 4 (14.3) |
Corticosteroid use at baseline: yes | 6 (22.2) | 14 (50.0) | 7 (28.0) | 9 (32.1) |
Mean DAS28-CRP score | 5.71 ± 1.021 | 5.62 ± 0.931 | 5.63 ± 0.774 | 5.71 ± 1.122 |
 Mean DAS28-ESR score | 7.19 ± 1.033 | 7.07 (0.876) | 6.99 (0.741) | 7.2 (1.023) |
 Mean 66 swollen joint count | 12.4 ± 8.78 | 12.8 (9.13) | 15.8 (10.92) | 13.6 (7.00) |
 Mean 68 tender joint count | 23.0 ± 13.12 | 24.1 (11.91) | 25.4 (12.49) | 24.2 (13.24) |
Mean patient’s global assessment of disease activity | 68.6 ± 17.6 | 68.8 ± 15.17 | 65.9 ± 15.69 | 66.8 ± 16.27 |
Mean patient assessment of pain (VAS), mm | 77.3 ± 17.43 | 75.0 ± 17.73 | 72.6 ± 13.7 | 69.3 ± 19.69 |
Mean physician’s global assessment of disease activity (mm) | 68.6 ± 17.22 | 68.8 ± 15.17 | 65.9 ± 15.69 | 66.8 ± 16.27 |
 Mean HAQ-DI | 1.84 ± 0.67 | 1.61 ± 0.509 | 1.52 ± 0.516 | 1.49 ± 0.605 |
 Median CRP, mg/L | 7.91 | 3.95 | 6.29 | 9.41 |
 Mean CRP, mg/L | 17.12 ± 22.63 | 12.24 ± 15.4 | 8.92 ± 8.9 | 24.55 ± 60.5 |
 Mean MBDA score | 48.15 ± 17.515 | 47.92 ± 20.17 | 41.91 ± 15.47 | 48.77 ± 17.75 |
 Mean C1M, ng/mL | 35.45 ± 19.355 | 35.65 ± 24.99 | 35.36 ± 26.26 | 46.68 ± 45.56 |
SF-36 mental health | 49.1± 17.92 | 50.4 ± 17.19 | 57.2 ± 18.08 | 50.6 ±18.24 |
SF-36 vitality | 30.1 ± 17.51 | 31.5 ± 14.6 | 36.1 ± 14.35 | 31.7 ± 16.67 |